ReviewOncology reviews2026
The CALLY index in cancer research: a comprehensive review.
Review in Oncology reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic Value of the C-Reactive Protein-Albumin-Lymphocyte Index in Hepatobiliary and Pancreatic Cancers: A Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Is the CALLY Index the Best Tool for Predicting Survival in Patients with Primary Soft Tissue Sarcomas?Diagnostics (Basel, Switzerland) · 2026Article
- Long-term postdischarge immunonutrition management in elective colorectal cancer surgery patients an interim analysis of a Chinese multicenter randomised controlled trial.Metabolism open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review focuses on the CALLY index in cancer, exploring its theoretical foundations, epidemiological insights, diagnostic and prognostic applications, therapeutic implications, controversies, and future perspectives. The CALLY index, based on C - reactive protein, albumin, and lymphocyte levels, has shown potential in predicting cancer prognosis and guiding treatment. Multiple studies across various cancer types indicate its association with survival outcomes, yet its widespread clinical adoption faces challenges. By synthesizing current research, this review aims to provide a comprehensive understanding of the CALLY index, highlighting its strengths, limitations, and potential for advancing cancer management in precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.